Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.46 |
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24781284 | 0.88 | SLC6A9 (0.52) | SLC6A9EGFRTEAD1BTKKMT2A | |
| SCHEMBL24780804 | 0.83 | TEAD1 (0.48) | SLC6A9EGFRTEAD1BTKDCUN1D1 | |
| SCHEMBL23592000 | 0.83 | TEAD1 (0.48) | SLC6A9EGFRTEAD1BTKDCUN1D1 | |
| SCHEMBL21958811 | 0.81 | SLC6A9 (0.46) | SLC6A9EGFRTEAD1BTKDCUN1D1 | |
| SCHEMBL21958167 | 0.80 | TEAD1 (0.54) | EGFRTEAD1BTKKMT2AMEN1 | |
| SCHEMBL21958780 | 0.78 | TEAD1 (0.50) | EGFRTEAD1BTKKMT2AMEN1 | |
| SCHEMBL21958713 | 0.77 | EGFR (0.66) | EGFRTEAD1BTKKMT2ADCUN1D1 | |
| SCHEMBL21958800 | 0.77 | SLC6A9 (0.42) | SLC6A9EGFRTEAD1BTKDCUN1D1 | |
| SCHEMBL21958241 | 0.75 | TEAD1 (0.50) | EGFRTEAD1BTKDCUN1D1GRIN2B | |
| SCHEMBL21958238 | 0.74 | DCUN1D1 (0.53) | EGFRTEAD1KMT2AMEN1DCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2021133896-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2020081572-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | SLC6A9 1179/4885EGFR 3966/4885TEAD1 1/4885 |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | SLC6A9 1701/4885EGFR 2755/4885TEAD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.